NVDA
NVIDIA
-- 118.798 TSLA
Tesla
-- 237.355 INTC
Intel
-- 24.275 PLTR
Palantir
-- 86.610 AAPL
Apple
-- 215.420 
Update Thursday 1/9/25
$Acumen Pharmaceuticals (ABOS.US)$ Acumen Pharmaceuticals Announces Journal of Prevention of Alzheimer's Disease Publication of the Company's Phase 1 INTERCEPT-AD Study, Including Target Engagement, Dosing Regimen and Safety Findings
GlobeNewswire· 08:0011mins
GlobeNewswire· 08:0011mins
Phase 1 INTERCEPT-AD data published in Journal of Prevention of Alzheimer's Disease supports continued development of sabirnetug (ACU193) for treatment of early Alzheimer's disease (AD)
Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E
Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025
Sabirnetug demonstrated selective, dose-dependent target engagement of amyloid beta oligomers (AβOs), statistically significant amyloid plaque reduction within higher dose cohorts, and low overall levels of ARIA-E
Phase 2 ALTITUDE-AD clinical trial of sabirnetug is ongoing with enrollment completion expected 1H 2025
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
corbotron : not that I'll invest in this one but I like seeing advances in ad announced, gives me hope having it terribly run within my family. I'm young (35) so hopefully by 60 when it tends to start in my family there will be a cure
Trytosaveabit OP corbotron : I’m sorry to hear that! Yes I pray for you and all affected by this horrific disease, that a cure will be found.